The 2026 trading year has kicked into gear, and while some stocks are already pushing higher into the green, others are ...

AI isn’t neutral in women’s health. It involves learning from visibility gaps shaped by brand safety, search authority, and ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Artificial intelligence is no longer just a tool that sits outside our heads. It is starting to seep into how we remember, decide and even imagine, blurring the line between human thought and machine ...

The Arts Council of Princeton (ACP) has announced a three-person exhibition, “Divergent Forms,” featuring the work of artists ...

Accurate classification of wetland vegetation is essential for biodiversity conservation and carbon cycle monitoring. This study developed an adaptive ...

Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the company's lead drug. Read more here.

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

DNA Ginkgo Bioworks Holdings, Inc.